U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06953726) titled 'Comparing the Safety and Efficacy of Apixaban and Rivaroxaban' on April 23.
Brief Summary: * The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation. The two most commonly-used anticoagulants will be compared: apixaban (Eliquis) and rivaroxaban (Xarelto). They are considered by many doctors to have similar benefits and risks, but no one knows for sure.
* The trial only enrolls patients with a diagnosis of atrial fibrillation ("A Fib").
* We will measure, in about 10,000 VA patients nationally, whether the r...